These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
612 related articles for article (PubMed ID: 18163452)
1. The variability of levodopa response in Parkinson's disease: is sensitization reversible? Jabre MG; Bejjani BP Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452 [No Abstract] [Full Text] [Related]
2. [Pergolide: a useful agonist for the treatment of Parkinson disease]. Bonnet AM; Houeto JL Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908 [TBL] [Abstract][Full Text] [Related]
3. Pergolide and Parkinson's disease: new preparation. No clear benefit. Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497 [TBL] [Abstract][Full Text] [Related]
4. Medical hazards of the internet: gambling in Parkinson's disease. Larner AJ Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457 [No Abstract] [Full Text] [Related]
5. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905 [TBL] [Abstract][Full Text] [Related]
6. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122 [TBL] [Abstract][Full Text] [Related]
7. Dopamine agonists as primary treatment in Parkinson's disease. Rinne UK Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394 [No Abstract] [Full Text] [Related]
8. [Optimization of the treatment of Parkinson's disease using dopamine agonists]. Rinne UK Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430 [No Abstract] [Full Text] [Related]
9. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738 [No Abstract] [Full Text] [Related]
10. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease. Olanow CW; Alberts MJ Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266 [No Abstract] [Full Text] [Related]
11. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?]. Defer GL Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847 [No Abstract] [Full Text] [Related]
12. The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa. MacMahon DG Age Ageing; 2003 May; 32(3):244-5. PubMed ID: 12720606 [No Abstract] [Full Text] [Related]
13. [Early treatment of Parkinson's disease with levodopa]. Odekerken VJ; Post B; Verschuur CV; de Bie RM Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822 [TBL] [Abstract][Full Text] [Related]
14. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
15. Identifying poor symptom control in Parkinson's disease. Scott L Nurs Times; 2006 Mar 21-27; 102(12):30-2. PubMed ID: 16594560 [TBL] [Abstract][Full Text] [Related]
16. Levodopa in the treatment of Parkinson's disease: current controversies. Gerlach M; Reichmann H; Riederer P Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130 [No Abstract] [Full Text] [Related]